I am pleased to say that a commentary to the G20 on behalf of the DRIVE-AB Steering Committee has now gone live in the Online First section of Lancet Infectious Diseases. The article is not Open Access so you’ll have to download it for yourself (link below).
The commentary summarises some of DRIVE-AB’s preliminary findings that are pertinent to the G20 discussions as this list of recommendations:
- Immediately fill the gap of US$250 million per year in push funding; existing mechanisms require additional financing and are well suited for an immediate in-flow of extra financing
- Implement market entry reward pilots to learn about the operationalisation of such models
- Request that regional and global banking institutions (such as the European Investment Bank and the World Bank) examine potential novel financial instruments to support further antibacterial R&D funding
- Establish a mechanism for multinational coordination and collaboration
- Develop health technology assessment processes and rules of reimbursement to consider the resistance situation and capture antibiotic societal value
DRIVE-AB’s complete findings will be published and presented at the DRIVE-AB conference in Brussels on Sept 5–6, 2017.
Best wishes and stayed tuned for further developments! –jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx
Upcoming events of note outside of the mainstream large meetings:
- 10-11 July: FDA workshop on bacteriophage therapies
- 19 July: FDA workshop on combination therapy for TB
- 5-9 Sep: ASM-ESCMID conference on antibiotic R&D, including the CARB-X + GARDP Antibiotic Bootcamp
- 13 Sep 2017 (DC): FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance
Link to online article: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30404-8/abstract